http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4199502-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_05ff905fdc49089f5f25746eaeb40190 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2400-40 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08B37-0075 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08B37-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-86 |
| filingDate | 1978-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1980-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6039c1253c567af93f70cea56b0a283 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ca7c204f747eb270b83f17b8ed78d46 |
| publicationDate | 1980-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-4199502-A |
| titleOfInvention | Removal of heparin from blood plasma samples using an insoluble protamine reaction product |
| abstract | This invention relates to a method for the removal of heparin from heparin-containing blood plasma test samples using an insoluble protamine reaction product, without adversely affecting subsequent testing of the plasma for clotting time. Protamine sulfate or a combination of protamine sulfate and serum albumin is cross-linked with glutaraldehyde to form an insoluble reaction product which is capable of adsorbing heparin. According to the method of this invention, excess amounts of either of the cross-linked protamine reaction products are added to blood plasma samples containing heparin and the mixture is agitated for a time sufficient to permit adsorption of substantially all heparin present. The insoluble protamine heparin complex formed is removed from the plasma along with any excess insoluble protamine reaction product. Aliquots of the heparin-free plasma may be subjected to coagulation tests in order to determine true clotting time. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11378577-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5705396-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108291911-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5151192-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3370064-A4 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5000854-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4800016-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0697463-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5286388-A |
| priorityDate | 1978-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 62.